Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
687.80M | 673.30M | 820.00M | 744.60M | 714.80M | Gross Profit |
381.30M | 379.70M | 450.00M | 364.30M | 373.30M | EBIT |
-396.20M | 4.20M | 74.00M | 8.90M | -46.10M | EBITDA |
-345.60M | 50.60M | 77.80M | 8.90M | -2.00M | Net Income Common Stockholders |
-392.10M | -61.80M | 50.50M | 6.30M | -27.20M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
107.70M | 87.70M | 127.70M | 118.50M | 111.50M | Total Assets |
1.15B | 1.69B | 1.79B | 1.59B | 1.67B | Total Debt |
170.20M | 209.10M | 280.00M | 187.50M | 248.80M | Net Debt |
62.50M | 121.40M | 152.30M | 69.00M | 137.30M | Total Liabilities |
325.70M | 456.10M | 495.70M | 330.70M | 416.30M | Stockholders Equity |
828.50M | 1.24B | 1.29B | 1.26B | 1.26B |
Cash Flow | Free Cash Flow | |||
82.90M | 14.60M | 71.60M | 66.30M | -22.70M | Operating Cash Flow |
100.70M | 32.40M | 90.90M | 87.30M | -2.50M | Investing Cash Flow |
-27.50M | 21.60M | -135.40M | -21.00M | -24.20M | Financing Cash Flow |
-49.10M | -94.20M | 56.70M | -55.30M | -70.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $112.72B | 26.71 | 8.42% | 3.19% | 2.72% | 4.48% | |
76 Outperform | $63.63B | 36.81 | 6.92% | 1.80% | 5.89% | 42.05% | |
73 Outperform | $22.43B | 25.42 | 7.24% | 0.85% | 3.84% | -9.29% | |
67 Neutral | $13.84B | 19.52 | 15.78% | ― | 1.75% | 50.25% | |
54 Neutral | $16.08B | 136.07 | -9.24% | 2.93% | -14.00% | -184.82% | |
52 Neutral | $660.15M | 45.80 | -37.42% | ― | -2.54% | -546.91% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% |
On March 17, 2025, Avanos Medical announced the appointment of David Pacitti as its new Chief Executive Officer, effective April 14, 2025. Pacitti, who previously held leadership roles at Siemens Healthineers and Abbott Vascular, brings extensive industry expertise and a strategic vision to the company. His appointment is expected to drive Avanos’s next phase of growth and success, with a focus on delivering breakthrough medical device solutions and enhancing long-term value for stakeholders.
Avanos Medical announced its participation in the 43rd Annual JP Morgan Healthcare Conference, highlighting strategic transformation initiatives aimed at optimizing their product portfolio and enhancing profitability. The company is focusing on market expansion through innovation, restructuring sales organizations, and cost management initiatives to drive growth and deliver value to stakeholders.